QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Evolent Health, Inc. (EVH)

Healthcare

No action
Fundamental
2
Sentiment
3
Technical
3

Do Nothing: fundamentalScore is 2 (below the required floor of 3); the strategy requires fundamentalScore ≥ 3 before any bullish long entry, so the constructive chart (price above all key moving averages, MACD positive, pullback-to-support hold at 4.63) is not actionable.

Analysis as of 2026-11-14· more than 2 trading days ago

Company overview

Evolent Health, Inc. provides clinical and administrative solutions to healthcare payers and providers in the U.S. through its Evolent Health Services and Clinical Solutions segments. The company offers an integrated platform for health plan management and care management services, focusing on value-based care, particularly in oncology and cardiology.

Fundamental

weak
Fundamental2
Elevated risk

Evolent Health faces elevated risk due to leverage, margin compression, and concentrated revenue sources.

Leveraged, low-margin healthcare-services turnaround: revenue is inflecting strongly but adjusted EBITDA is shrinking, the medical expense ratio has deteriorated to 93%, and roughly $821M of net debt equals about 6.2x guided adjusted EBITDA. The headline loss is largely a non-cash impairment artifact and no solvency trigger exists (unqualified audit opinion, no covenant breach, no maturity before 2029, positive operating cash flow), but unquantified DOJ exposure, heavy payer concentration and further goodwill-impairment risk leave this in elevated-risk, watchlist territory rather than investable.

Sentiment

fair
Sentiment3
Mixed / forming

Sentiment is mixed with post-earnings digestion and conflicting catalyst signals.

Post-earnings digestion dominates: the 2026-11-05 Q3 print read bearish on the tape — revenue missed consensus by roughly 1.2% and shares fell about 7% despite +51% revenue growth and in-line adjusted EPS — and it is offset by two post-print price-target raises to $6/$7 (Needham, Oppenheimer) and a new Humana/American Oncology Network prior-authorization model, all at announced confidence. The sentiment delta is indeterminate (the 30–90-day baseline holds only two scored items, below the three-item threshold), a moderate red-flag cap applied for conflicting catalyst signals, and no severe flag fired because the August 2025 DOJ False Claims Act CID is stale background overhang.

Technical

fair
Technical3
Constructive chart

The technical setup is constructive with price above key averages, but trend confirmation is lacking.

Constructive but not decisive short-term chart: the 2026-11-13 bar closed at $4.90, above the SMA20 (4.63), SMA50 (4.22), SMA200 (3.92), EMA9 (4.74), EMA21 (4.59), WMA9/21 (4.79/4.65), DEMA14 (4.83), TEMA14 (4.86) and the daily VWAP (4.79) — a full bull stack. MACD is positive with the line above signal and the histogram turning up (0.16 / 0.13 / +0.02), RSI14 58.87 and Williams %R -11.96 show momentum recovering without being stretched, and the 11-13 session dipped to 4.63 before closing on the high (a pullback-to-support shape that held above the 20-day). Two things keep this from scoring higher: ADX14 at 22.55 is sub-trending, so the trend is not established, and price is still working off a lower-high sequence from the July high (6.26) inside an October–November 4.18–5.01 base. ATR14 0.33 (6.7% of price) gives ample swing range and volume is adequate (20-day average dollar volume ~$7.9M; last three sessions ~$5.5M). Technical score 3 = mixed, several bullish confirmations against an unconfirmed trend. The chart read is valid, but no trade is actionable because the fundamental override gate fails (fundamentalScore 2 < 3).

You’re looking at 2026-11-14 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.